Uncategorized
Cure SMA Announces the Publication of “Impact of Early Intervention on Motor Milestone Achievement in Spinal Muscular Atrophy”
Cure SMA is pleased to announce the publication of “Impact of early intervention on motor milestone achievement in spinal muscular atrophy: Insights from Cure SMA […]
Meet Winnie, the 11-Year-Old Author Helping Kids Face Surgery
Winnie is an 11-year-old living with spinal muscular atrophy (SMA) who loves musicals, drawing, and playing sports with her brothers. After her recent surgery, she […]
Cure SMA Launches Their “This Gen Next 10” Campaign
Today, Cure SMA is proud to launch our year-end campaign: This Gen, Next 10. It’s a chance to look at where this community started, how […]
Adults with SMA Share Their Unmet Needs and Independence Barriers in Washington D.C.
This week, the unmet health and everyday living needs of adults with spinal muscular atrophy (SMA) took center stage in Washington, DC, in an event […]
Biogen Shares Update on the Salanersen Development Program
(opens in new tab) From newly opened Phase 3 studies enrolling infants through adults to the first participants already dosed in the U.S. and Japan, […]
Genentech Shares Highlights from an Unforgettable Week at the Annual SMA Conference
(opens in new tab) From a lively “Evryday Café” exhibit hall experience to an advocacy reception featuring conversations on policy and access, Genentech recaps a […]
Biogen Shares Conference Highlights and New High Dose SPINRAZA Resources
From the High Dose SPINRAZA symposium to a family-friendly poster session, Biogen recaps their experience at this year’s Annual SMA Conference and highlights new tools […]
Visit the Cure SMA Hub at This Year’s Annual SMA Conference
The Cure SMA Hub is your go-to space at the Annual SMA Conference to learn about key Cure SMA programs and opportunities for involvement. Stop […]
Breakthroughs Built Together: Help Cure SMA Close a Critical Research Funding Gap
This spring, we’re asking our community to help us invest $1 million in basic research by June 30. Every breakthrough in spinal muscular atrophy (SMA) research has […]
Scholar Rock Resubmits Biologics License Application (BLA) for Apitegromab to the FDA
Today, Scholar Rock announced that it has resubmitted its Biologics License Application (BLA) to the Food and Drug Administration (FDA) for apitegromab, an investigational therapy […]